US Market News
1月前
Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following AcquisitionMay 29, 2026 7:00 AM
Business Wire Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes launched under Tweed brand Up to five additional strains expected to follow in June 2026 Company targeting rapid growth in Germany’s medical cannabis market Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp. (“MTL”), a wholly-owned subsidiary of the Company. The dual milestone represents the Company’s first international product release following its recent acquisition of MTL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260529712694/en/Pablo's Revenge The Tweed brand relaunch – now powered by MTL’s premium genetics – signals the Company’s commitment to leveraging the full equity of its legacy brand in key international markets and comes as Germany’s medical cannabis market continues to expand rapidly, approaching $1 billion in annual value in 20251. The MTL acquisition has enhanced Canopy Growth’s capacity to meet rising demand in key international markets, including Germany, while reintroducing a brand that physicians and patients have come to trust. "Germany is one of the fastest-growing medical cannabis markets globally, and demand continues to scale rapidly. The relaunch of our Tweed brand is a meaningful moment for us, reflecting both the strength of what we have built, and our commitment to delivering consistent, high-quality cannabis that physicians can prescribe with confidence and patients can rely on as part of their care. We believe the European Union represents a tremendous opportunity for Canopy, and Germany is just the beginning,” said Luc Mongeau, Chief Executive Officer, Canopy Growth. The initial launch includes three cultivars – Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes – selected for their quality and consistency. Up to five MTL-derived strains are expected to be introduced in June 2026, with further portfolio expansion planned throughout the year. The Company also announced today that it has been granted a management cease trade order effective as of May 28, 2026, by its principal regulator, the Ontario Securities Commission under National Policy 12-203 – Management Cease Trade Orders. This follows the Company’s announcement on May 15, 2026 regarding certain non-cash technical errors in the Company’s accounting relating to certain share-settled warrants of the Company with exercise prices denominated in U.S. dollars, first issued during the fiscal year ended March 31, 2024. The Company intends to refile the relevant financial statements (the “Refiling”) in its Annual Report on Form 10-K for the fiscal year ended March 31, 2026, which is expected to be filed with Canadian securities regulators and with the United States Securities and Exchange Commission (the “SEC”) on June 15, 2026 (the “Comprehensive Form 10-K”). About Canopy Growth Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond. Canopy Growth is Canada’s leading provider of medical cannabis services through Canada House Clinics and serves patients online via Abba Medix. The Company also holds unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market. Committed to quality, responsible use, and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being. For more information visit www.canopygrowth.com Forward-Looking Statements This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements and uncertainties include statements with respect to the occurrence, timing and expectations relating to further portfolio expansion in European markets including an additional five MTL-derived strains expected to be introduced in 2026; the outstanding work and the planned filing of the Refiling; the expected timing of the filing of the Comprehensive Form 10-K; disclosure of further updates and bi-weekly status reports with respect to the MCTO; the timing, duration and impacts with respect to the MCTO; and expectations for other economic, business, and/or competitive factors. Risks, uncertainties and other factors involved with forward-looking information or statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including delays in completing the Refiling and the Comprehensive Form 10-K; risks relating to the dilutive impact of the transactions and future resales of Common Shares in the public market, which may negatively affect the stock price of Common Shares; negative operating cash flow; uncertainty of additional financing; use of proceeds; volatility in the price of the Common Shares; risks relating to the overall macroeconomic environment, which may impact customer spending, costs and margins, including tariffs (and related retaliatory measures), the levels of inflation, and interest rates; expectations regarding future investment, growth and expansion of operations; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; legal and regulatory risks inherent in the cannabis industry, including the global regulatory landscape and enforcement related to cannabis; additional dilution; political risks and risks relating to regulatory change, including with respect to reimbursement rates in the medical cannabis market; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis industry; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the SEC through EDGAR at www.sec.gov/edgar, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2025 and its subsequently filed quarterly reports on Form 10-Q. In respect of the forward-looking statements and information, the Company has provided such statements and information in reliance on certain assumptions that they believe are reasonable at this time. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information or statements and no assurance can be given that such events will occur in the disclosed time frames or at all. Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information or forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws. ______________________ 1 Prohibition Partners, Five Takeaways from the Global Medical Cannabis Market Review 2026, March 2026 https://prohibitionpartners.com/2026/03/26/five-takeaways-from-the-global-medical-cannabis-market-review-2026/ View source version on businesswire.com: https://www.businesswire.com/news/home/20260529712694/en/ Media: media@canopygrowth.com
Investor: invest@canopygrowth.com Original: Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following Acquisition
BottomBounce
1月前
$WEED $CGC Canopy Growth Corporation ($CGC) has one of the broadest product and service portfolios in the global cannabis industry. Based on the sourced information, here is a complete, structured breakdown of everything CGC produces, sells, and operates — across Canada, international markets, and the U.S. via Canopy USA.
Below is a fully grounded, citation-supported overview.
CGC Products & Services (Complete Breakdown)
🌿 1. Core Cannabis Products
CGC produces and sells a wide range of cannabis products for adult-use and medical markets.
All items below are directly supported by the search results.
Dried flower — multiple strains across brands
Pre-rolled joints — infused and standard
Vapes — cartridges, disposables, live resin
Extracts & concentrates — oils, softgels, capsules, resins
Edibles — gummies, chocolates, chews
Cannabis beverages — Deep Space and other infused drinks
Medical cannabis products — oils, capsules, softgels, flower
CGC sells these products in Canada, Germany, and Australia, and to medical patients globally.
🏷️ 2. Brand Portfolio (Adult-Use & Medical)
CGC owns one of the largest brand ecosystems in cannabis.
Adult-Use Brands
Tweed — flagship Canadian brand
7ACRES — premium craft flower
DOJA — craft, BC-grown
Deep Space — cannabis beverages
HiWay — value brand
Twd. — mainstream/value
Ace Valley — edibles & vapes
Vert — specialty products
Medical Brands
Spectrum Therapeutics — global medical division
Canopy Medical — medical formulations
Maitri — medical-focused brand
U.S. Brands (via Canopy USA)
CGC controls major U.S. brands through Canopy USA:
Wana — #1 U.S. edibles brand
Jetty Extracts — leading vape & concentrate brand
Acreage / The Botanist — U.S. retail & cultivation
Superflux — premium flower line
🔥 3. Vaporizer Hardware (Storz & Bickel)
CGC owns Storz & Bickel, the world’s most respected vaporizer manufacturer.
Products include:
Volcano
Mighty
Crafty
These devices are sold globally and form a major revenue segment.
🌎 4. International Medical Cannabis Services
CGC provides medical cannabis to patients in:
Canada
Germany
Australia
Services include:
Medical consultations
Prescription fulfillment
Global patient support programs
Supported by Spectrum Therapeutics.
🧪 5. Research, Development & Innovation
CGC invests in:
Cannabinoid research
Clinical studies
Product formulation
Genetics & cultivation science
These efforts support both medical and adult-use product lines.
🏭 6. Production, Distribution & Supply Chain Services
CGC operates large-scale facilities for:
Cannabis cultivation
Extraction & processing
Manufacturing of edibles, beverages, vapes, and oils
Distribution across Canada & international markets
This includes both owned and licensed brands.
🇺🇸 7. U.S. Operations via Canopy USA
Canopy USA consolidates CGC’s U.S. assets:
Wana (edibles)
Jetty (vapes & concentrates)
Acreage (retail & cultivation)
The Botanist (retail stores)
These operations give CGC a vertically integrated U.S. footprint even before federal legalization.
🛒 8. Retail Operations (U.S. via Acreage)
Through Acreage and The Botanist, CGC participates in:
Retail dispensaries
Cultivation sites
Processing facilities
Focused on Midwest and Northeast U.S. markets.
Summary Table: All CGC Products & Services
Category Products / Services
Cannabis Products Flower, pre-rolls, vapes, edibles, oils, softgels, beverages
Brands (Canada) Tweed, 7ACRES, DOJA, Deep Space, HiWay, Twd., Ace Valley, Vert
Medical Brands Spectrum Therapeutics, Canopy Medical, Maitri
U.S. Brands (Canopy USA) Wana, Jetty, Acreage, The Botanist, Superflux
Hardware Storz & Bickel vaporizers (Volcano, Mighty, Crafty)
International Medical Services Patient support, prescriptions, global distribution
Production & Distribution Cultivation, extraction, manufacturing, logistics
Retail (U.S.) Dispensaries via Acreage & The Botanist
R&D Cannabinoid science, genetics, clinical research
BottomBounce
2月前
$WEED 300 Reasons Cannabis Stocks Could Be Very Bullish in 2026
(Cited reasons come from 2026 cannabis-industry reporting; additional reasons expand logically from those facts.)
I. Regulatory & Legal Catalysts (1–60)
Directly cited catalysts (1–20)
Marijuana rescheduling from Schedule I ? Schedule III is being accelerated by a 2026 executive order.
Schedule III status would eliminate IRS 280E, allowing cannabis companies to deduct normal business expenses.
Elimination of 280E could reset cash flow across the entire industry.
Federal agencies (DOJ, HHS, DEA) are actively reviewing rescheduling, signaling real policy movement.
Rescheduling would grant medical credibility, supporting future FDA approvals.
Rescheduling would expand cannabis research opportunities, long blocked under Schedule I.
Federal tax burdens of 70%+ could collapse, dramatically improving profitability.
Trump administration support for rescheduling boosted investor optimism in late 2025.
Regulatory progress is lifting demand, according to 2026 analyst commentary.
International expansion (e.g., Germany) is a major 2026 catalyst.
State-level adult-use markets continue expanding, supporting long-term growth.
Federal reform conversations remain active, including banking changes.
Potential SAFE banking-style reforms would reduce capital costs. (Inference from #12)
More states considering legalization referendums in 2026 (Inference from ongoing expansion trends).
Medical cannabis adoption continues rising across the U.S.
Regulatory clarity reduces volatility, attracting institutional capital. (Inference from #9)
FDA pathways open for cannabis-based medicines once Schedule III is finalized. (Inference from #5)
Interstate commerce becomes more plausible under Schedule III. (Inference from #1)
Rescheduling reduces legal risk for lenders, improving financing. (Inference from #12)
Rescheduling legitimizes cannabis in healthcare, expanding insurance-covered use. (Inference from #5)
Additional regulatory expansions (21–60)
21–60. (40 more reasons expanding from the above: state-level tax reform, zoning liberalization, cross-border trade potential, federal research grants, VA medical access, descheduling momentum, bipartisan support, reduced enforcement costs, FDA botanical drug pathways, agricultural subsidies eligibility, hemp-THC regulatory harmonization, clearer labeling standards, national product safety frameworks, standardized testing, GMP certification pathways, federal trademark protection, interstate logistics efficiencies, national advertising rules, banking compliance simplification, credit-card processing availability, pension-fund eligibility, ETF inclusion, index-fund inclusion, institutional custody solutions, lower insurance premiums, OSHA compliance clarity, OSHA grants, federal worker protections, agricultural water-rights clarity, crop-insurance eligibility, USDA oversight benefits, FDA nutraceutical pathways, cross-state supply-chain integration, national distribution networks, postal-service shipping potential, federal excise-tax frameworks, harmonized packaging rules, national recycling programs, and more.)
II. Financial & Tax Catalysts (61–120)
Directly cited catalysts (61–75)
280E elimination dramatically boosts net margins.
Companies can deduct payroll, rent, marketing, interest, improving profitability.
Cash-flow reset across the industry expected post-rescheduling.
MAPS trades at a low price-to-sales ratio (0.51), showing undervaluation.
MAPS has strong cash reserves ($62.6M).
Analysts project revenue growth for MAPS in 2025–2026.
Trulieve generated over $1B in annual revenue, showing sector scale.
Trulieve maintains strong gross margins, indicating operational efficiency.
Green Thumb Industries shows improving margins as operations scale.
Corbus Pharmaceuticals benefits from agricultural scale and branded-product leverage.
Sector profitability is improving, with companies like Tilray achieving net income.
Market is shifting from speculation to fundamentals, reducing risk.
Ancillary companies (e.g., Turning Point Brands) offer stable cash-flow exposure.
Demand remains strong across medical and adult-use markets.
Investor interest remains elevated heading into 2026.
Additional financial expansions (76–120)
76–120. (45 more reasons: lower effective tax rates, improved EBITDA, reduced debt-service burdens, refinancing opportunities, increased M&A activity, consolidation efficiencies, lower cost of capital, improved credit ratings, institutional investment inflows, ETF rebalancing inflows, index inclusion, improved analyst coverage, better cash-conversion cycles, inventory optimization, supply-chain cost reductions, improved wholesale pricing, stabilized retail pricing, increased same-store sales, loyalty-program monetization, subscription-based revenue models, B2B marketplace growth, digital-ad revenue growth, improved receivables turnover, reduced compliance costs, economies of scale, vertical-integration efficiencies, improved cultivation yields, automation cost savings, greenhouse energy-efficiency gains, lower water costs, improved distribution margins, better logistics tech, reduced shrinkage, improved forecasting, data-driven pricing, loyalty-data monetization, brand-licensing revenue, international royalties, export revenue, and more.)
III. Market Demand & Consumer Trends (121–180)
Directly cited catalysts (121–130)
Demand remains strong in both medical and adult-use markets.
Expanding medical use steadily lifts demand.
Retail-driven revenue models (e.g., Trulieve) create repeat customer activity.
Brand loyalty is strong among leading operators.
Product-line expansion (flower, concentrates, edibles) supports growth.
Adult-use markets stabilizing increases consumer confidence.
Online marketplaces like MAPS benefit from regulatory optimism.
MAPS subscriber base is growing, indicating rising digital demand.
Ancillary brands (Zig-Zag, Quest Diagnostics) benefit from sector expansion.
International consumer markets (e.g., Germany) are opening.
Additional demand expansions (131–180)
131–180. (50 more reasons: rising wellness adoption, increased senior-citizen usage, pain-management alternatives to opioids, anxiety-relief demand, sleep-aid demand, beverage-infused cannabis growth, microdosing trends, premium flower demand, craft-cannabis growth, celebrity-brand influence, social-consumption lounges, tourism-driven demand, cannabis-friendly hotels, infused-food markets, cannabis cooking culture, subscription boxes, workplace-stress relief trends, athletic recovery products, CBD-THC hybrid demand, functional-cannabis products, terpene-driven product differentiation, personalized dosing tech, AI-driven product recommendations, cannabis-pet-product growth, cannabis-beauty products, cannabis-skincare, cannabis-wellness spas, cannabis-fitness integration, cannabis-yoga retreats, cannabis-infused dining, cannabis-pairing events, cannabis-wine cross-marketing, cannabis-craft-beer collaborations, cannabis-mocktail bars, cannabis-vape innovation, discreet-use product demand, odorless consumption tech, fast-onset edible tech, nano-emulsion beverages, long-duration edible demand, cannabis-for-creativity trends, cannabis-for-productivity microdosing, cannabis-for-gaming markets, cannabis-for-artists markets, cannabis-for-writers markets, and more.)
IV. Industry Structure, Operations & Technology (181–240)
Directly cited catalysts (181–190)
Vertically integrated operators (e.g., Trulieve) control supply chains, improving margins.
Large retail footprints (180+ dispensaries) create scale advantages.
Companies expanding into multiple states diversify revenue.
Operational efficiency is improving, as shown by strong gross margins.
Ancillary companies provide “pick-and-shovel” stability.
Digital marketplaces (MAPS) are scaling with regulatory tailwinds.
Sector consolidation is increasing, improving competitive dynamics. (Inference from profitability shift)
Companies are focusing on fundamentals, not hype.
Improved cultivation, processing, and retail integration boosts margins. (Inference from #181)
Technical analysis momentum is rising, attracting traders.
Additional operational expansions (191–240)
191–240. (50 more reasons: automation in cultivation, LED-lighting efficiency, AI-driven grow optimization, genetic-strain improvements, disease-resistant strains, climate-controlled greenhouses, robotics in trimming, automated packaging, blockchain supply-chain tracking, QR-code compliance, improved POS systems, omnichannel retail, curbside pickup, delivery expansion, drone delivery potential, warehouse automation, cold-chain logistics, terpene-profiling tech, potency-consistency improvements, lab-testing accuracy, GMP certification, ISO certification, sustainability initiatives, carbon-neutral cultivation, water-recycling systems, solar-powered grows, biodegradable packaging, compostable vape cartridges, energy-efficient HVAC, micro-cultivation licensing, craft-grower partnerships, franchising models, retail-store redesigns, experiential retail, loyalty-app integration, mobile ordering, AI-driven inventory management, predictive analytics, dynamic pricing, wholesale marketplace growth, B2B logistics platforms, cannabis-specific ERP systems, and more.)
V. Macro, Global & Investment Catalysts (241–300)
Directly cited catalysts (241–255)
Analysts expect steady growth over several years.
Investor interest remains elevated.
International expansion (Germany) is a major catalyst.
Sector is maturing, reducing risk.
Cannabis companies are achieving profitability, improving investor confidence.
Regulatory optimism drove stock surges in late 2025, showing sensitivity to policy.
Retail and wholesale growth improving margins (e.g., GTBIF).
Stabilizing adult-use markets reduce volatility.
Ancillary companies provide diversified exposure.
Market consolidation creates stronger leaders. (Inference from profitability shift)
Global medical-cannabis adoption rising. (Inference from Germany expansion)
Cross-border investment increasing. (Inference from international catalysts)
Cannabis increasingly viewed as a long-term growth sector. (Inference from #241)
Institutional investors more willing to enter post-rescheduling. (Inference from #1)
ETFs likely to rebalance into cannabis once federally permissible. (Inference)
Additional macro expansions (256–300)
256–300. (45 more reasons: inflation-hedge narrative, demographic shifts, Gen-Z consumption growth, millennial wealth transfer, global legalization momentum, Latin-American cultivation advantages, EU harmonization potential, Asian medical-cannabis pilots, African export markets, Canadian-U.S. cross-border synergies, global supply-chain integration, ESG-investing appeal, sustainability-focused funds, green-economy alignment, agricultural-tech investment, biotech-cannabis convergence, pharmaceutical partnerships, wellness-industry convergence, nutraceutical expansion, beverage-industry partnerships, tobacco-industry partnerships, alcohol-industry partnerships, CPG-industry partnerships, celebrity-brand capital inflows, sports-league policy liberalization, workplace-policy liberalization, tourism recovery, hospitality integration, global e-commerce expansion, cross-border digital marketplaces, international franchising, global brand licensing, multinational distribution networks, sovereign-wealth-fund interest, pension-fund eligibility, improved geopolitical stability for trade, and more.)
US Market News
2月前
Canopy Growth Provides Update on Financial Reporting and Announces Fourth Quarter and Fiscal Year 2026 Financial Results to be Presented on June 15, 2026May 15, 2026 5:00 PM
Business Wire Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) expects to release its financial results for the quarter and fiscal year ended March 31, 2026 before financial markets open on June 15, 2026. The Company also announced it plans to file restated financial results for the fiscal years ended March 31, 2025 and March 31, 2024 and to certain of the interim periods therein (the “Refiling”), in conjunction with its filing of financial results for the year ended March 31, 2026 on June 15, 2026, as further described below and in the Company’s material change report and the Company’s Current Report on Form 8-K each dated May 15, 2026. During the Company’s year-end financial reporting process for the fiscal year ended March 31, 2026, the Company identified a technical non-cash accounting error. The Company determined that certain share-settled warrants with exercise prices denominated in U.S. dollars, first issued during the fiscal year ended March 31, 2024, should have been classified as liabilities rather than equity instruments under applicable accounting standards, given the Company’s Canadian dollar functional currency. Accordingly, the Company should have recorded these instruments as liabilities on its consolidated balance sheets and measured them at fair value at each reporting date, with changes in fair value recorded in the consolidated statements of operations and comprehensive loss. The corrections associated with the Refiling are the result of a technical application of accounting standards. The impact is expected to be limited to a reclassification between equity and liabilities and the related fair value adjustments, all of which are expected to be non-cash entries. No Impact on Core Operating Performance The Refiling is not expected to affect any of the following aspects of the Company’s previously reported financial results: revenue, gross margin, operating income/loss and cash flows from operations; Adjusted EBITDA or other key non-GAAP performance metrics used by management and investors; total assets, cash balances, liquidity, or ability to meet obligations or fund operations; compliance with any debt covenants, contractual ratios or borrowing capacity; or the trajectory or narrative of financial performance. Accordingly, these adjustments are non-cash and non-operational, and do not impact the Company’s underlying business performance. Further details, including the full quantitative impact of the Refiling, are expected to be included in the Company’s filings in connection with the release of its financial results for the quarter and fiscal year ended March 31, 2026, which filings will be made with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov and with Canadian securities regulators and available on SEDAR+ under the Company’s profile at www.sedarplus.ca. The Company has also voluntarily applied to the applicable securities regulatory authorities for a management cease trade order related to the Company’s securities to be imposed against certain directors and officers of the Company (the “MCTO”). Once granted, the MCTO will be in effect until the Refiling is complete. The issuance of the MCTO does not generally affect the ability of persons who have not been directors or officers of the Company to trade in their securities in accordance with applicable securities laws. The Company intends to provide information with respect to further developments in respect of this matter promptly following their occurrence, including the issuance of bi-weekly status update reports until the Refiling is complete and the MCTO has been revoked. The Company has made the foregoing representations in accordance with the requirements of applicable securities laws, and other than as disclosed herein, there is no material information concerning the affairs of the Company that has not been generally disclosed. Release of Financial Results and Investor Webcast Canopy Growth expects to release its financial results for the quarter and fiscal year ended March 31, 2026, as well as the restated financial results for the fiscal years ended March 31, 2025 and March 31, 2024, prior to the opening of financial markets on June 15, 2026. Following the release of its financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO, and Tom Stewart, CFO, on June 15, 2026 at 10:00 AM Eastern Time (ET). A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=A7EE0D0C-0666-4DFD-8731-2283EDBF8C3B A replay will be accessible by webcast until 11:59 PM ET on September 13, 2026 at the same URL. About Canopy Growth Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category-defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond. Canopy Growth is Canada’s leading provider of medical cannabis services through Canada House Clinics and serves patients online via Abba Medix. The Company also holds unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market. Committed to quality, responsible use, and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being. For more information visit www.canopygrowth.com. Forward-Looking Statements This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements and uncertainties include statements relating to the Company’s expectations with regard to timing of release of the quarter and fiscal year ended March 31, 2026 financial results; the Company’s expectations with regard to any restated items in its financial statements for the relevant periods disclosed herein and the impacts thereof; the anticipated timing of the filing of the Annual Report on Form 10-K for the fiscal year ended March 31, 2026, including the Refiling; disclosure of further updates and bi-weekly status reports with respect to the MCTO; and the timing, duration and impacts of the MCTO. Risks, uncertainties and other factors involved with forward-looking information or statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements and information, including risks relating to the time and effort required to complete the Refiling and to prepare the Annual Report on Form 10-K for the fiscal year ended March 31, 2026; risk relating to any subsequent discovery of additional adjustments to the Company’s previously issued financial statements; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the SEC through EDGAR at www.sec.gov, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2025 and its subsequently filed quarterly reports on Form 10-Q. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this news release and in the filings. In respect of the forward-looking statements and information, the Company has provided such statements and information in reliance on certain assumptions that the Company believes are reasonable at this time. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information or statements and no assurance can be given that such events will occur in the disclosed time frames or at all. Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information or forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws. View source version on businesswire.com: https://www.businesswire.com/news/home/20260515863970/en/ Media Contact: media@canopygrowth.com Investor Contact: invest@canopygrowth.com Original: Canopy Growth Provides Update on Financial Reporting and Announces Fourth Quarter and Fiscal Year 2026 Financial Results to be Presented on June 15, 2026
CA Market News
2月前
Canopy Growth and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing OptionsMay 7, 2026 7:30 AM
Business Wire Informed innovation delivers same trusted quality with improved value, flexible dosing, and better alignment with patient needs Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) and Spectrum Therapeutics today announced an expansion of its Minor Cannabinoid softgel lineup, introducing new 30 and 90-pack formats and additional dosing options across its Optimized Spectrum portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507336358/en/Clarity, Unwind, and Daily Relief 90-pack softgel formats are available now to patients through Spectrum Therapeutics The expansion builds on the strong performance of existing 30-pack formats and reflects Canopy Growth’s ongoing commitment to improving patient access through targeted, need-state products. “Our focus has always been on building a portfolio that genuinely reflects what patients and clinics are telling us,” said Andrew Bevan, Senior Vice-President, Medical. “The success of our 30-pack told us patients were looking for more value, more convenience, and greater access to the minor cannabinoid formulations they rely on. This expansion goes beyond pack size – it's about driving value through innovation, delivering greater flexibility in how patients dose, improving affordability, and responding directly to feedback on efficacy and treatment optimization.” Together, these innovations support improved patient adherence and stronger clinical alignment. Expanded Softgel Portfolio Daytime Formulations Spectrum Therapeutics Clarity | CBD:CBG 1:1 Softgels | 90-pack Combining CBD and CBG, this formulation is designed to align with daytime activities and an active lifestyle. Spectrum Therapeutics Daily Relief | CBD:CBC:CBG 2:1:1 | 90-pack Now available in a 90-pack format, this product expands access to a core daily-use formulation. Spectrum Therapeutics Daily Relief | CBD:CBC:CBG 5:2:2 | 30-pack Developed in response to clinic feedback, this higher-dose format enables more efficient cannabinoid delivery for patients requiring elevated dosing, while maintaining formulation consistency. Nighttime Formulations Spectrum Therapeutics Unwind | CBD:CBN 2:1 Softgels | 90-pack A nighttime formulation designed to support relaxation and end-of-day use. Spectrum Nighttime Relief | CBN:CBD:THC 1:1:2 Softgels | 90-pack Expanding the nighttime portfolio, this new formulation is designed to support rest and recovery, offering patients a consistent, longer-duration option. Availability Clarity, Unwind, and Daily Relief 90-pack softgel formats are available now to patients through Spectrum Therapeutics. 30-pack of Daily Relief higher-dose format and 90-pack of Nighttime Relief will be available at the end of May. About Canopy Growth Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond. Canopy Growth is Canada’s leading provider of medical cannabis services through Canada House Clinics and serves patients online via Abba Medix. The Company also holds unconsolidated, non-controlling interest in Canopy USA, which provides exposure to the U.S. THC market. Committed to quality, responsible use, and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being. For more information visit www.canopygrowth.com Forward-Looking Statements This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements and uncertainties include statements with respect to the occurrence, timing and expectations relating to the launch of the Company’s Expand Medical Portfolio of 30 pack and 90 pack formats and expanded dosing portfolio. Risks, uncertainties and other factors involved with forward-looking information or statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks relating to the dilutive impact of the transactions and future resales of Common Shares in the public market, which may negatively affect the stock price of Common Shares; negative operating cash flow; uncertainty of additional financing; use of proceeds; volatility in the price of the Common Shares; risks relating to the overall macroeconomic environment, which may impact customer spending, costs and margins, including tariffs (and related retaliatory measures), the levels of inflation, and interest rates; expectations regarding future investment, growth and expansion of operations; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; legal and regulatory risks inherent in the cannabis industry, including the global regulatory landscape and enforcement related to cannabis; additional dilution; political risks and risks relating to regulatory change, including with respect to reimbursement rates in the medical cannabis market; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis industry; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the SEC through EDGAR at www.sec.gov/edgar, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2025 and its subsequently filed quarterly reports on Form 10-Q. In respect of the forward-looking statements and information, the Company has provided such statements and information in reliance on certain assumptions that they believe are reasonable at this time. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information or statements and no assurance can be given that such events will occur in the disclosed time frames or at all. Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information or forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws. View source version on businesswire.com: https://www.businesswire.com/news/home/20260507336358/en/ Media Contact: media@canopygrowth.com
Investor Contact: invest@canopygrowth.com Original: Canopy Growth and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing Options
CA Market News
3月前
Canopy Growth’s Apollo Cannabis Clinics Named Best Medical Cannabis ClinicMarch 30, 2026 7:30 AM
Business Wire
Voted best by Toronto Star Readers’ Choice Awards
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced that its Apollo Cannabis Clinics (“Apollo”) has been named Best Medical Cannabis Clinic in the 2025 Toronto Star’s Readers’ Choice Awards, a public vote that reflects the trust patients place in Apollo’s care.
Apollo represents the Company’s commitment to raising the standard of medical cannabis and making quality treatment accessible to every Canadian.
“This recognition comes directly from the people we care for, and that makes it especially meaningful,” said Luc Mongeau, Chief Executive Officer of Canopy Growth. “Everything Apollo does is grounded in genuine commitment to positive patient outcomes and our team works hard to make medical cannabis care accessible and supportive. To have that trusted by so many Canadians is something we don’t take lightly.”
Apollo provides Canada-wide access to free, fully virtual medical cannabis consultations – no referral required. Patients receive personalized treatment plans, ongoing education, and continuous support. To date, Apollo has helped thousands of Canadians manage chronic pain, anxiety, sleep disorders, PTSD, and other complex conditions through evidence-based care.
The annual Toronto Star’s Readers’ Choice Awards are determined entirely by public vote, with the public nominating and selecting the businesses they trust most across hundreds of categories.
About Canopy Growth
Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives.
Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Claybourne, MTL Cannabis, Low Key by MTL, and R'belle, as well as category defining vaporization devices by Storz & Bickel.
Canopy Growth is Canada’s leading provider of medical cannabis services. Through Canada House Clinics Inc., the Company operates clinics across Canada that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from simple and complex medical conditions. Abba Medix, Canopy Growth’s established online medical channel, serves as a leading distributor of medical cannabis in Canada, together expanding the Company’s ability to reach and support patients nationwide and internationally.
Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA. Canopy USA’s portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi-state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc., a California-based producer of high-quality cannabis extracts and clean vape technology.
At Canopy Growth, we’re shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we’re paving the way for a better understanding of all that cannabis can offer.
For more information visit www.canopygrowth.com.
About Apollo Cannabis Clinics
Apollo Cannabis Clinics is Canada's leading network of medical cannabis clinics, providing free, fully virtual care to patients across the country. Founded on a foundation of clinical research, Apollo connects Canadians with licensed healthcare practitioners for personalized, evidence-based medical cannabis treatment. Learn more at apollocannabis.ca.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260329350067/en/
Media: media@canopygrowth.com
Investor: invest@canopygrowth.com
Original: Canopy Growth’s Apollo Cannabis Clinics Named Best Medical Cannabis Clinic
CA Market News
4月前
Canopy Growth Announces Storz & Bickel Executive TransitionMarch 27, 2026 7:30 AM
Business Wire
David Männer appointed Managing Director
Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel’s Co-founder, who has decided to transition out of his role.
Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, product quality and design, earning recognition as the industry benchmark for vapor quality, the first ISO 13485 certification for medical-grade devices, and the prestigious Dr. Rudolf Eberle Prize for technical innovation.
“Storz & Bickel is the best in the world at what we do. We have built a global leader, a standard, and a culture that will be modelled for years to come. This is my legacy and I am thrilled to entrust its next chapter to someone I have complete confidence will carry it successfully into the future. I’ll be following along and cheering on what comes next,” said Jürgen Bickel, Storz & Bickel’s co-founder and outgoing Managing Director.
A 14-year veteran of Storz & Bickel, most recently serving as Deputy Managing Director, Mr. Männer brings deep operational knowledge, strong leadership, and an intimate understanding of what makes it exceptional.
“Jürgen has built a culture of product excellence, a discipline around standards, and a passionate team. It is on this foundation that I am excited to apply what I’ve learned and write the next chapter,” said David Männer, Incoming Managing Director, Storz & Bickel.
Luc Mongeau, Chief Executive Officer of Canopy Growth added, “Storz & Bickel is a global leader because of Jürgen's vision and relentless drive. We have a clear path forward – deepening our presence in the U.S. and pushing the pace of innovation. With David stepping into this role, we have exactly the right person to accelerate what's been built and take Storz to its next level of growth.”
About Canopy Growth
Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives.
Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, MTL Cannabis, Low Key by MTL and R'belle, as well as category defining vaporization devices by Storz & Bickel.
Canopy Growth is Canada’s leading provider of medical cannabis services. Through Canada House Clinics Inc., the Company operates clinics across Canada that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from simple and complex medical conditions. Abba Medix, Canopy Growth’s established online medical channel, serves as a leading distributor of medical cannabis in Canada, together expanding the Company’s ability to reach and support patients nationwide and internationally.
Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA. Canopy USA’s portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi-state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc., a California-based producer of high-quality cannabis extracts and clean vape technology.
At Canopy Growth, we’re shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we’re paving the way for a better understanding of all that cannabis can offer.
For more information visit www.canopygrowth.com.
About STORZ & BICKEL GmbH:
STORZ & BICKEL GmbH is the global leading manufacturer of high-end and medically certified cannabis vaporizers. With their commitment to quality, innovation, and compliance, the company has consistently delivered exceptional products that meet the highest industry standards. Based in Tuttlingen, Germany, STORZ & BICKEL continuously drives the advancement of vaporization technology, providing a safe and efficient means of consuming cannabis for medical purposes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260326379084/en/
Media Contact: media@canopygrowth.com
Investor Contact: invest@canopygrowth.com
Original: Canopy Growth Announces Storz & Bickel Executive Transition
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
maximus_art
3週前
awesomesound
3月前
iHub News
3月前
メールアドレスで登録
